Eli Lilly's (LLY) triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
- In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss, a level long associated with bariatric surgery
- Individuals with a baseline BMI ≥35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks
#UNITED STATES#USD#EUR#CANADA#GERMANY#JAPAN#JPY#MRO#UNITED KINGDOM#GBP#EUROPE#DEERE & CO#ELI LILLY & CO#LLY.US#MARATHON OIL CORP#ON SEMICONDUCTOR CORP#CENTENE CORP#QUANTUM CORP#SOFTWARE#FEDERAL CORP#VICE PRESIDENT#FOREX#EQUITIES#METALS#EU SESSION#NICKEL#COMMODITIES#SILVER#AGRICULTURAL & FARM MACHINERY#MANAGED HEALTH CARE#PHARMACEUTICALS#IT CONSULTING & OTHER SERVICES#SEMICONDUCTORS#METALS & MINING#MACHINERY#HEALTH CARE PROVIDERS & SERVICES#PHARMACEUTICALS (GROUP)#IT SERVICES#SEMICONDUCTORS & SEMICONDUCTOR EQUIPMENT (GROUP)#MEDIA#MATERIALS (GROUP)#CAPITAL GOODS#HEALTH CARE EQUIPMENT & SERVICES (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FINANCIAL SERVICES#SOFTWARE & SERVICES#SEMICONDUCTORS & SEMICONDUCTOR EQUIPMENT#MEDIA & ENTERTAINMENT#S&P 500 INDEX#NASDAQ 100 INDEX#CNC#COGNIZANT TECHNOLOGY SOLUTIONS CORP#CTSH#DE#ELI LILLY AND CO#LLY#ON#DXY#TRADE#US EQUITIES#CHINA#TRADE#AI